Clinical Trials
9 trialsNCT06536413 2026-04-03
ATRA
The Methodist Hospital Research Institute
Phase 1/2 Recruiting
NCT04700176 2025-02-25
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
Hackensack Meridian Health
Phase 2 Terminated
NCT06158412 2025-02-19
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT02751255 2023-04-28
DARA/ATRA
Amsterdam UMC, location VUmc
Phase 1/2 Completed
NCT02401295 2017-02-23
ATRA, Celecoxib, and Itraconazole as Maintenance
University of Iowa
Phase 1 Completed
NCT01985477 2016-09-14
Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00006220 2013-02-06
Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy
Washington University School of Medicine
Phase 1/2 Terminated
NCT00400556 2006-11-17
ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells
Peter MacCallum Cancer Centre, Australia
Phase 1 Completed